In a study – conducted for Outsourcing-Pharma.com – research analyst Sudarsan Pakaravoor said a lull in innovation for rare and orphan indications has led vendors to seek more innovative ways to work with industry.
He said the traditional industry, made up of a series of contract research organisations (CROs) and vendors is too “fragmented” and therefore the discovery process is divided.
To read the original article: Open source developers could swipe biz from CROs
